Activated Carbon Nanoparticles Loaded with Metformin for Effective Against Hepatocellular Cancer Stem Cells

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2023 Jun 7

PMID 37283712

Authors

Lan Sun

Hong-Juan Yao

Jing-Cao Li

Bao-Quan Zhao

Yong-An Wang

Ying-Ge Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatocellular cancer stem cells (CSCs) play crucial roles in hepatocellular cancer initiation, development, relapse, and metastasis. Therefore, eradication of this cell population is a primary objective in hepatocellular cancer therapy. We prepared a nanodrug delivery system with activated carbon nanoparticles (ACNP) as carriers and metformin (MET) as drug (ACNP-MET), which was able to selectively eliminate hepatocellular CSCs and thereby increase the effects of MET on hepatocellular cancers.

Methods: ACNP were prepared by ball milling and deposition in distilled water. Suspension of ACNP and MET was mixed and the best ratio of ACNP and MET was determined based on the isothermal adsorption formula. Hepatocellular CSCs were identified as CD133 cells and cultured in serum-free medium. We investigated the effects of ACNP-MET on hepatocellular CSCs, including the inhibitory effects, the targeting efficiency, self-renewal capacity, and the sphere-forming capacity of hepatocellular CSCs. Next, we evaluated the therapeutic efficacy of ACNP-MET by using in vivo relapsed tumor models of hepatocellular CSCs.

Results: The ACNP have a similar size, a regular spherical shape and a smooth surface. The optimal ratio for adsorption was MET: ACNP=1:4. ACNP-MET could target and inhibit the proliferation of CD133 population and decrease mammosphere formation and renewal of CD133 population in vitro and in vivo.

Conclusion: These results not only suggest that nanodrug delivery system increased the effects of MET, but also shed light on the mechanisms of the therapeutic effects of MET and ACNP-MET on hepatocellular cancers. ACNP, as a good nano-carrier, could strengthen the effect of MET by carrying drugs to the micro-environment of hepatocellular CSCs.

Citing Articles

Nanotechnology for the Diagnosis and Treatment of Liver Cancer.

Cai Y, Wang W, Jiao Q, Hu T, Ren Y, Su X Int J Nanomedicine. 2024; 19:13805-13821.

PMID: 39735328 PMC: 11681781. DOI: 10.2147/IJN.S490661.

Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.

Molecular Biomarkers and Signaling Pathways of Cancer Stem Cells in Colorectal Cancer.

Omran M, Fouda M, Mekkawy S, Tabll A, Abdelaziz A, Omran A Technol Cancer Res Treat. 2024; 23:15330338241254061.

PMID: 38794896 PMC: 11128179. DOI: 10.1177/15330338241254061.

References

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B . Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3(11):1451-61. DOI: 10.1158/1940-6207.CAPR-10-0157. View

Xue J, Li R, Gao D, Chen F, Xie H . CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer. Int J Nanomedicine. 2020; 15:5701-5718. PMC: 7426108. DOI: 10.2147/IJN.S257527. View

Liu J, Li M, Song B, Jia C, Zhang L, Bai X . Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 2011; 31(2):264-70. DOI: 10.1016/j.urolonc.2011.01.003. View

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-8. DOI: 10.2337/diacare.29.02.06.dc05-1558. View

Yin A, Miraglia S, Zanjani E, Almeida-Porada G, Ogawa M, Leary A . AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1998; 90(12):5002-12. View

Wu Y, Wu P . CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009; 18(8):1127-34. DOI: 10.1089/scd.2008.0338. View

Burgos-Ojeda D, Rueda B, Buckanovich R . Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012; 322(1):1-7. PMC: 4431611. DOI: 10.1016/j.canlet.2012.02.002. View

Liu Y, Pu Y, Sun L, Yao H, Zhao B, Zhang R . Folic Acid Functionalized γ-Cyclodextrin C₆₀, A Novel Vehicle for Tumor-Targeted Drug Delivery. J Biomed Nanotechnol. 2018; 12(7):1393-403. DOI: 10.1166/jbn.2016.2275. View

Hirsch H, Iliopoulos D, Tsichlis P, Struhl K . Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69(19):7507-11. PMC: 2756324. DOI: 10.1158/0008-5472.CAN-09-2994. View

10.

Bao B, Wang Z, Ali S, Ahmad A, Azmi A, Sarkar S . Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2011; 5(3):355-64. PMC: 3786260. DOI: 10.1158/1940-6207.CAPR-11-0299. View

11.

Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez J . Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle. 2010; 9(18):3807-14. View

12.

Xie J, Yong Y, Dong X, Du J, Guo Z, Gong L . Therapeutic Nanoparticles Based on Curcumin and Bamboo Charcoal Nanoparticles for Chemo-Photothermal Synergistic Treatment of Cancer and Radioprotection of Normal Cells. ACS Appl Mater Interfaces. 2017; 9(16):14281-14291. DOI: 10.1021/acsami.7b02622. View

13.

Zhang P, Li H, Tan X, Chen L, Wang S . Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013; 37(3):207-18. DOI: 10.1016/j.canep.2012.12.009. View

14.

Jiang S, Wang X, Zhang Z, Sun L, Pu Y, Yao H . CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells. Int J Nanomedicine. 2016; 11:5505-5518. PMC: 5098746. DOI: 10.2147/IJN.S115428. View

15.

Zhong Y, Shuzheng M, Yingge Z . Using activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agents. J Nanosci Nanotechnol. 2010; 10(12):8603-9. DOI: 10.1166/jnn.2010.2492. View

16.

Liu B, Yang W, Che C, Liu J, Si M, Gong Z . A Targeted Nano Drug Delivery System of AS1411 Functionalized Graphene Oxide Based Composites. ChemistryOpen. 2021; 10(4):408-413. PMC: 8015732. DOI: 10.1002/open.202000226. View

17.

Huang P, Wang X, Liang X, Yang J, Zhang C, Kong D . Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater. 2018; 85:1-26. DOI: 10.1016/j.actbio.2018.12.028. View

18.

Missol-Kolka E, Karbanova J, Janich P, Haase M, Fargeas C, Huttner W . Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate. 2010; 71(3):254-67. DOI: 10.1002/pros.21239. View

19.

Zhang X, Li F, Zheng Y, Wang X, Wang K, Yu Y . Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog . Oxid Med Cell Longev. 2019; 2019:9078209. PMC: 6393877. DOI: 10.1155/2019/9078209. View

20.

Yao H, Sun L, Li J, Zhou X, Li R, Shao R . A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells. Int J Nanomedicine. 2020; 15:7013-7034. PMC: 7522319. DOI: 10.2147/IJN.S260163. View